Literature DB >> 9527102

Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase.

F Tatò1, G L Vega, S M Grundy.   

Abstract

Marked lowering of plasma total and low-density lipoprotein cholesterol levels that occur during treatment of dyslipidemia with pharmacologic doses of nicotinic acid result from hepatotoxicity. Therefore, a marked reduction in low-density lipoprotein may suggest generalized liver toxicity and drug treatment should be discontinued.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9527102     DOI: 10.1016/s0002-9149(97)01016-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Pathophysiology of dyslipidaemia in the metabolic syndrome.

Authors:  G D Kolovou; K K Anagnostopoulou; D V Cokkinos
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

Review 2.  The benefits of niacin in atherosclerosis.

Authors:  S Tavintharan; M L Kashyap
Journal:  Curr Atheroscler Rep       Date:  2001-01       Impact factor: 5.113

Review 3.  Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review.

Authors:  L Iughetti; B Predieri; F Balli; S Calandra
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

4.  Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters.

Authors:  Helen Vosper
Journal:  Clin Med Insights Cardiol       Date:  2011-09-19

5.  Niacin-Induced Anicteric Microvesicular Steatotic Acute Liver Failure.

Authors:  Kenneth Leung; Michael Quezada; Zhengshan Chen; Gary Kanel; Neil Kaplowitz
Journal:  Hepatol Commun       Date:  2018-09-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.